ACADIA Pharmaceuticals (ACAD) Earnings Analysis
ACADIA Pharmaceuticals (ACAD) has no confirmed upcoming earnings date. Last quarter (2026-02-25) it beat with EPS 1.6 USD vs 0.137 USD est (+1067.9%). It has beaten estimates in 2/2 recent quarters (100%). Trailing P/E 11.19.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ACAD next report earnings?
No confirmed upcoming earnings date is currently scheduled for ACAD. This page updates as the calendar is published.
ACAD earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-25 | 1.6 USD | 0.137 USD | +1067.9% | Beat |
| 2025-02-26 | 0.17 USD | 0.13 USD | +30.8% | Beat |
Beat rate: 2/2 (100%) over reported quarters with consensus data.
ACAD valuation and analyst view
| Trailing P/E | 11.19 |
|---|---|
| Trailing EPS | 2.203 USD |
| Price / book | 3.41 |
| Dividend yield | 0.00% |
| Market cap | 4.28B |
| Analyst consensus | Buy (26 buy / 10 hold / 1 sell) |
| Avg price target | 36.25 USD |
Related research pages
Frequently asked questions
When is ACADIA Pharmaceuticals (ACAD)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for ACAD. This page updates as the calendar is published.
Did ACAD beat earnings last quarter?
In its 2026-02-25 report, ACAD posted EPS of 1.6 USD versus a 0.137 USD estimate — a beat of 1067.9%.
What is ACAD's earnings track record?
Over the last 2 reported quarters with consensus data, ACAD beat estimates 2 times (100%).
What is ACAD's current P/E ratio and EPS?
ACAD trades at a trailing P/E of 11.19 on trailing EPS of 2.203006151879285 USD.
What do analysts rate ACAD?
Analyst consensus is "Buy" across 37 ratings (0 strong buy, 26 buy, 10 hold, 1 sell, 0 strong sell). Average 12-month price target: 36.25 USD.